Rui Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B1

  • Latest Deal Amount
  • $28M

  • Investors
  • 12

Rui Therapeutics General Information

Description

Developer of universal cell therapy drugs, focused on advancing CAR-NK, UCAR-T, and CAR-γδT technologies for unmet clinical needs. The company specailises in proprietary cell drug platforms, viral delivery systems, CAR structure designs, and cryopreservation techniques, thereby targeting autoimmune diseases, inflammatory conditions, fibrosis, and anti-ageing applications through first-in-class therapeutic innovations.

Contact Information

Website
www.ruitherapeutics.com
Formerly Known As
Nanjing Enrui Kainuo Biotechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 801, Building C6, Room 801, Building C6, Jiangsu Life Science Park
  • Qixia District
  • Nanjing, Jiangsu 210000
  • China
+86 135
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Manufacturing, Life Sciences
Corporate Office
  • Room 801, Building C6, Room 801, Building C6, Jiangsu Life Science Park
  • Qixia District
  • Nanjing, Jiangsu 210000
  • China
+86 135

Rui Therapeutics Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rui Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC (Series B1) 15-Sep-2025 $28M Completed Generating Revenue
4. Early Stage VC (Series B) 15-May-2025 Completed Generating Revenue
3. Early Stage VC 18-Apr-2024 Completed Generating Revenue
2. Secondary Transaction - Private 06-Feb-2024 Completed Generating Revenue
1. Early Stage VC 13-Jul-2023 Completed Generating Revenue
To view Rui Therapeutics’s complete valuation and funding history, request access »

Rui Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Green Pine Capital Partners Venture Capital Minority
Shenzhen Chongshi Private Equity Investment Fund Management PE/Buyout Minority
Shenzhen Nanshan Strategic Emerging Industry Investment Government Minority
Shenzhen Nanshan Venture Capital Venture Capital Minority
Tasly Holding Group Corporation Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

Rui Therapeutics FAQs

  • When was Rui Therapeutics founded?

    Rui Therapeutics was founded in 2021.

  • Where is Rui Therapeutics headquartered?

    Rui Therapeutics is headquartered in Nanjing, China.

  • What industry is Rui Therapeutics in?

    Rui Therapeutics’s primary industry is Drug Discovery.

  • Is Rui Therapeutics a private or public company?

    Rui Therapeutics is a Private company.

  • What is Rui Therapeutics’s current revenue?

    The current revenue for Rui Therapeutics is .

  • How much funding has Rui Therapeutics raised over time?

    Rui Therapeutics has raised $28M.

  • Who are Rui Therapeutics’s investors?

    Green Pine Capital Partners, Shenzhen Chongshi Private Equity Investment Fund Management, Shenzhen Nanshan Strategic Emerging Industry Investment, Shenzhen Nanshan Venture Capital, and Tasly Holding Group are 5 of 12 investors who have invested in Rui Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process